Eris Lifesciences · NSE: ERIS · BSE: 540596
Q2 FY24 results · Jul–Sep 2023
Eris Lifesciences reported revenue from operations of ₹505.30 crore (up 9.7% from Q2 FY23) and net profit of ₹122.31 crore (up 2.5% from Q2 FY23) for Q2 FY24 (Jul–Sep 2023), on a consolidated basis.
| Item | Q2 FY24 | Q2 FY23 | YoY | Q1 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 505.30 | 460.51 | +9.7% | 466.62 | +8.3% |
| Other income | 3.48 | 5.17 | −32.7% | 0.99 | +252.0% |
| Total income | 508.78 | 465.68 | +9.3% | 467.61 | +8.8% |
| Profit before tax | 126.24 | 120.93 | +4.4% | 112.48 | +12.2% |
| Net profit for the period | 122.31 | 119.38 | +2.5% | 93.65 | +30.6% |
| Attributable to shareholders of the company | 123.43 | 120.30 | +2.6% | 94.86 | +30.1% |
| EPS, basic (₹) | 9.08 | 8.84 | +2.7% | 6.97 | +30.3% |
| Net margin (%) | 24.2 | 25.9 | 20.1 |
| Item | Q2 FY24 | Q2 FY23 | YoY | Q1 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 409.71 | 355.37 | +15.3% | 411.29 | −0.4% |
| Other income | 6.97 | 6.15 | +13.4% | 4.03 | +73.2% |
| Total income | 416.68 | 361.52 | +15.3% | 415.31 | +0.3% |
| Profit before tax | 119.92 | 123.81 | −3.1% | 132.52 | −9.5% |
| Net profit for the period | 117.81 | 115.20 | +2.3% | 110.74 | +6.4% |
| EPS, basic (₹) | 8.66 | 8.47 | +2.2% | 8.14 | +6.4% |
| Net margin (%) | 28.8 | 32.4 | 26.9 |
Consolidated
- Filed with BSE
- 13 Nov 2023, 11:18 IST
- Board meeting
- 08 Nov 2023
- Period
- 01 Jul 2023 to 30 Sep 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 13 Nov 2023, 11:18 IST
- Board meeting
- 08 Nov 2023
- Period
- 01 Jul 2023 to 30 Sep 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE